All stock Upjohn-Mylan merger brings $12bn debt

By Mike Turner
30 Jul 2019

Pfizer has agreed to spin off its off-patent drug business Upjohn and merge it with generic drug company Mylan, in an all-share deal that will still see $12bn of debt raised.

Each Mylan share will be converted into a share of the new company. Pfizer shareholders will own 57% of the new entity, with Mylan shareholders owning the rest.

It will create a new pharmaceutical firm with forecast pro-forma 2020 revenues of around $20bn, with pro-forma Ebitda for the same ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.